Foghorn Therapeutics Inc. is focused on the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. The Company's Gene Traffic Control platform allows it to identify, validate and potentially drug targets within the chromatin regulatory system. It is initially focused in oncology. It is developing FHD-286, a selective, allosteric ATPase inhibitor and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors. FHD-286 is allosteric and orally available, small-molecule, enzymatic inhibitor of BRG1 and BRM, that is initially being developed for the treatment of acute myeloid leukemia (AML) and uveal melanoma. FHD-609 is an intravenous, small molecule protein degrader of BRD9. The Company is also engaged in developing additional programs targeting large populations that include selective BRM and selective ARID1B modulators.